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Abstract: Rosacea is a common, chronic, skin condition characterized by recurrent episodes 
of facial flushing, transient or persistent erythema, papules, pustules, and telangiectasias, in a 
symmetrical facial distribution. The etiology of rosacea remains unknown and this condition 
represents a therapeutic challenge because of its chronic nature, progression, potential for 
disfigurement and psychological impact. Although there is no curative therapy for rosacea, 
the most widely used systemic agents are oral tetracycline derivatives, including tetracycline, 
doxycycline, and minocycline. This article reviews the available evidence for the use of doxy-
cycline, a second-generation tetracycline, in the treatment or rosacea.
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Rosacea is a common, chronic dermatologic condition, whose cause remains unknown. 
It has a higher prevalence in fair-skinned individuals and most commonly affects indi-
viduals between the ages of 30 and 50, women being more affected than men.1,2 The 
diagnosis of rosacea requires the presence of one or more of the following primary 
features concentrated on the central area of the face: flushing (transient erythema), 
nontransient erythema, papules and pustules, and telangiectasia.3 Rosacea represents 
a therapeutic challenge because of its chronic nature, progression, potential for dis-
figurement, and psychological impact.
Tetracycline compounds were the first systemic drugs used in the treatment of rosa-
cea, and have been the mainstay therapeutics for more than 40 years, although it has just 
recently been approved by the FDA for the treatment of this condition.4,5 Doxycycline, 
a second-generation tetracycline, exhibits superior pharmacokinetic properties and lesser 
toxicity than first-generation tetracyclines.6 They also posses antiangiogenic and anti-
inflammatory properties that make it a promising therapeutic option in the treatment 
of rosacea.7 This paper reviews the safety and efficacy of doxycycline in the treatment 
of rosacea with emphasis on those clinical studies that support its use.
Pharmacology of doxycycline
Chemistry
The basic chemical structure of tetracyclines consists of a tetracyclic naphtacene 
carboxamide ring system.7 The structures of tetracycline, doxycycline, and mino-
cycline are shown in Figure 1. Doxycycline differs structurally from the tetracy-
cline molecule in the modifications of substituent at positions 5 and 6 of the ring Clinical, Cosmetic and Investigational Dermatology 2009:2 130
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system, which make it more lipid soluble. Minocycline has 
a dimethylamino substituent at position 7.
Absorption
Semi-synthetic second-generation tetracyclines, doxycycline 
and minocycline, are better absorbed after oral administra-
tion than first-generation counterparts due to their higher 
lipid solubility.8–11 Pooled data from studies show that mean 
absorption of oral doxycyline is close to 95%.8,9,12,13 After oral 
administration, the absorption of doxycycline is rapid, being 
detectable in blood in as little as 15 minutes.12
Distribution, metabolism, and excretion
Doxycycline is widely distributed in tissues, including the 
skin, because of its high lipophilicity.8–12,14,15 No doxycycline 
metabolites have been found in blood, urine, or feces.12 
Doxycycline elimination occurs mainly through the gastro-
intestinal tract. Renal elimination accounts for 30% to 40% 
of the administered dose.12 Doxycycline serum levels are 
minimally affected in patients with renal insufficiency and 
require no adjustments in dosage.8–9,16
Mechanism of action
Bacteriostatic effects of tetracyclines are due to inhibition of 
protein synthesis, by binding to the 30S subunit on the bacte-
rial ribosome, where they interfere with the binding of the 
aminoacyl tRNA to the acceptor site on the mRNA-ribosome 
complex.14
Several studies have shown that tetracylines, including 
doxycycline, have immunomodulating properties.7,14,17 These 
anti-inflammatory effects have been used to target several 
pathophysiological mechanisms in rosacea.
Tetracyclines have been shown to inhibit white cell 
movement during inflammation by interfering with calcium-
dependent microtubular assembly and to inhibit lymphocytic 
proliferation by blockage of blast tranformation.7,17–21 Tetracy-
clines have also been shown to inhibit arachidonic acid (AA) 
production from cell membrane components, in turn reducing 
the production of AA-derived proinflammatory mediators.22
Tetracyclines can inhibit proteolysis mediated by matrix 
metalloproteinases (MMPs) which are secreted by activated 
neutrophils.23,24 Studies in vivo and in vitro have demon-
strated inhibition of collagenase-3 (MMP-13), collagenase-2 
(MMP-8), collagenase-1 (MMP-1), gelatinase A (MMP-2), 
gelatinase B (MMP-9), and macrophage metalloelastase 
(MMP-12).25–27 Inhibition of gelatinases A and B, which 
break down the basement membrane of the capillary vessels, 
promotes integrity of the capillary wall, reduces sensitivity to 
vasodilatory stimuli, prevents capillary leakage, improves the 
integrity of connective tissue, and downregulates cytokines 
(eg, TNF-α and IL-1β) that assist in erythema and inflam-
mation associated with rosacea.28,29 Tetracyclines have 
also been shown to impair angiogenesis by the inhibition 
of MMPs, which may affect migration of endothelial cells 
during angiogenesis.30
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Tetracyclines may inhibit nitric oxide (NO) synthetase. 
This may prove beneficial in rosacea, as excess NO pro-
motes vasodilation and inhibition of extracellular matrix 
synthesis.31
Tetracyclines can affect molecular signaling pathways, 
such as the inhibition of calcium/calmodulin pathway 
and inhibition of protein kinase C activity. This results in 
decreased transcriptional activity for several MMPs, therefore 
reducing MMP-mediated extracellular matrix breakdown. 
Interference with this signaling also reduces vasodilation 
secondary to the decreased NO production.32–34
Several of these anti-inflammatory effects have been 
proven to occur with doxycycline (Table 1).
Doxycycline in rosacea
Subantimicrobial dose doxycycline
The use of doxycycline in rosacea has been proven in 
several clinical trials either alone or in combination with 
other therapies (Table 2). Before the introduction of 40 mg 
doxycycline monohydrate and its FDA approval in 2006 for 
the treatment of rosacea, there were several reports using 
subantimicrobial dose doxycycline hyclate 20 mg (SDD). 
Previous results of a study of doxycycline hyclate 20 mg 
twice daily for 6 months in the treatment of acne vulgaris 
had demonstrated a significant decrease in the clinical signs 
and symptoms without affecting the skin flora.35
The first study that reported the efficacy of SDD in the 
treatment of rosacea was an open-label study that included 
50 patients with all stages of rosacea.24 Patients were treated 
with SDD 20 mg twice daily for 8 weeks. After an average 
of 4 weeks, patients experienced an 80% to 100% clearing 
in inflammatory lesions and a 50% reduction in erythema. 
At the end of treatment, there were no reports of gastrointes-
tinal side effects, vaginitis, or photosensitivity.
A multicenter, randomized, double-blind, placebo-
controlled, 16-week clinical trial evaluated the use of SDD 
twice daily versus placebo in 134 patients with moderate 
rosacea.36 The assessment at week 16 relative to baseline 
showed a reduced lesion count (P = 0.009), decreased erythema 
score (P = 0.082), and global severity score (P = 0.034) in the 
study group compared with placebo. In the investigator’s global 
assessment scale (IGA), 13.1% of the study group patients 
achieved a score of 0 (clear) versus 1.5% of those with placebo 
(P = 0.014). Another single-center, randomized, double-blind, 
placebo-controlled trial evaluated the combined effect of SDD 
20 mg and metronidazole 0.75% topical lotion in the treatment 
of moderate-to-severe rosacea.37 Forty patients were random-
ized to receive SDD plus metronidaloze twice daily or placebo 
plus metronidazole twice daily for 12 weeks. SDD or placebo 
monotherapy continued for 4 weeks after metronidazole was 
discontinued. Results demonstrated a significant reduction 
from baseline in the total inflammatory lesion count at week 12 
(P  0.01) that was maintained at week 16, after 4 weeks of 
SDD as monotherapy (P  0.01). Secondary endpoints of 
global severity and erythema were also reduced significantly 
by the combination treatment. There were no between-group 
differences observed in adverse events and there were no cases 
of photosensitivity or vaginitis reported.
Anti-inflammatory dose doxycycline
Anti-inflammatory dose doxycycline (Oracea®; Galderma) 
refers to a specific 40 mg capsule formulation of doxycycline 
monohydrate containing 30 mg immediate-release and 10 mg 
delayed-release beads administered once daily and that is 
devoid of antibiotic activity.31 It was approved by the FDA 
in 2006 and is currently the only doxycyline formulation with 
FDA approval for the treatment of rosacea. Two phase 3, 
randomized, multicenter, double-blind, placebo-controlled, 
parallel-group monotherapy trials evaluated the use of once 
daily anti-inflammatory dose doxycycline (n = 269) or 
placebo (n = 268) for 16 weeks in the treatment of moder-
ate to severe rosacea.31 The mean changes from baseline 
in total inflammatory lesion count in the active treatment 
groups were −11.8 and −9.5 compared to −5.9 and −4.3 in 
the placebo arms (P  0.001). This decrease in lesion count 
was seen as early as 3 weeks, and there was a progressive 
continued reduction throughout the entire study period. Also, 
a statistically significant greater reduction in mean total 
erythema from baseline was observed in the actively treated 
group compared with placebo-treated subjects in one pivotal 
study (P = 0.017). Anti-inflammatory dose doxycycline once 
daily was well tolerated. The percentage of patients discon-
tinuing therapy because of adverse events was very low in 
both trials and was similar in both the active treatment and 
placebo group. Vaginal candidiasis and photosensitivity were 
not reported in the actively treated patients.
The efficacy of anti-inflammatory dose doxycycline in 
combination therapy for rosacea has also been reported. In a 
randomized, multicenter, double-blind, placebo-controlled, 
Table 1 Anti-inflammatory effects of doxycycline7
Inhibition of mitogen-induced human lymphocytic proliferation by 
blockage of blast transformation21
Inhibition of phospholipase A222
Inhibition of the expression of nitric oxide synthetase33,34
Accelerated degradation of nitric oxide synthetase34Clinical, Cosmetic and Investigational Dermatology 2009:2 132
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16-week trial, the combined effect of anti-inflammatory dose 
doxycycline 40 mg and metronidazole gel 1% once daily 
(n = 36) was compared to placebo capsule and metronidazole 
gel 1% once daily (n = 36) in adults with mild to moderate 
rosacea.38 After 12 weeks, metronidazole was discontin-
ued allowing for comparison of anti-inflammatory dose 
doxycycline and placebo from week 12 to week 16. At both 
4 weeks and 12 weeks assessments, the mean inflammatory 
lesion reduction from baseline was statistically significant in 
the anti-inflammatory dose doxycycline and metronidazole 
study arm (P = 0.008 week 4 and P = 0.002 week 12). From 
weeks 12 through 16, after discontinuation of metronida-
zole in both study arms, the improvement noted in the first 
12 weeks receded in subjects who received only placebo com-
pared with those subjects receiving only anti-inflammatory 
dose doxycycline. The results of this study indicate that 
concurrent use of anti-inflammatory dose doxycycline and 
metronidazole produces a greater magnitude of inflammatory 
lesion reduction than metronidazole alone.
Anti-inflammatory dose doxycycline 
compared with conventional dose 
doxycycline
When comparing anti-inflammatory dose doxycycline with 
anti-microbial dose doxycycline, a randomized, multi-center, 
double-blind, active-control, 16-week trial evaluated the 
efficacy of anti-inflammatory dose doxycycline (40 mg) 
and topical metronidazole gel 1% once daily (n = 44) versus 
conventional dose doxycycline (100 mg) and metronidazole 
gel 1% once daily (n = 47) in adults with moderate to severe 
rosacea.39 The mean change from baseline to week 16 in 
inflammatory lesion count was similar in both study groups 
and at all study visits. The mean change in erythema score 
from baseline was slightly greater at all time points in the 
Table 2 Studies of doxycycline in rosacea
Study No of 
subjects
Length of 
trial
Design Results Comments
Open-label24 50 8 weeks Doxycycline hyclate 20 mg 
twice daily
80% to 100% clearance 
of inflammatory lesions 
and a 50% reduction in 
erythema
No adverse events 
reported
Multicenter, randomized, 
double-blind, 
placebo-controlled36
134 16 weeks Doxycycline hyclate 20 mg 
twice daily vs placebo
reduced lesion count 
(P = 0.009), and global 
severity score  
(P = 0.034)
No adverse events 
reported
Single-center, 
randomized, 
double-blind, 
placebo-controlled37
40 16 weeks Doxycycline hyclate 
20 mg twice daily plus 
metronidazole 0.75% 
lotion vs placebo plus 
metronidazole 0.75% lotion. 
Metronidazole discontinued 
in both groups at week 12
reduced lesion count 
(P  0.01) at week 12 
that was maintained at 
week 16 after 4 weeks  
of doxycycline as 
monotherapy (P  0.01) 
and decreased global 
severity score (P = 0.046)
Gastrointestinal events 
more common in the 
subantimicrobial-dose 
doxycycline/metronidazole 
group (5 vs 2). No cases 
of photosensitivity or 
vaginitis reported
Multicenter, randomized 
double-blind, 
placebo-controlled31
573 16 weeks Doxycycline 40 mg once 
daily vs placebo
reduced lesion count 
(P .001), decreased 
erythema score 
(P = 0.017)
Adverse events were 
similar in both groups. No 
cases of photosensitivity 
or vaginitis reported
Multicenter, randomized 
double-blind, 
placebo-controlled38
72 16 weeks Doxycycline 40 mg plus 
metronidazole gel 1% once 
daily vs metronidazole 
gel 1% and placebo. 
Metronidazole discontinued 
at week 12 in both groups
reduced lesion count at 
week 4 (P = 0.008) and 
at week 12 (P = 0.002), 
decreased global severity 
score (P = 0.01) that 
was maintained through 
weeks 12 to 16
Improvement receded in 
the group that received 
only placebo from week 
12 to 16
Multicenter, randomized, 
double-blind, 
active-control39
91 16 weeks Doxycyline 40 mg plus 
metronidazole gel 1% once 
daily vs doxycycline 100 mg 
plus metronidazole gel 1% 
once daily
Similar mean change 
in inflammatory lesion 
count
Adverse events reported 
in 26 subjects in the 
100 mg group versus 
6 subjects in the 40 mg 
groupClinical, Cosmetic and Investigational Dermatology 2009:2 133
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40 mg group. This was statistically significant at week 12 
(P  0.04), but not at week 16. The most frequent adverse 
events included nausea, headache, influenza, nasopharyngitis, 
urticaria, diarrhea, esophageal pain, vomiting, abdominal 
pain, and upper abdominal pain in 32 patients. Of these, 
26 subjects were in the 100 mg group and 6 subjects were in 
the 40 mg group. This study demonstrates that although both 
anti-inflammatory dose doxycycline (40 mg) and conventional 
dose doxycycline (100 mg) are effective once-daily treatments 
for moderate to severe rosacea, a higher incidence of adverse 
events is associated with the use of the 100 mg dose.
Doxycycline in ocular rosacea
Several nonplacebo-controlled studies have reported 
improvement in the signs and symptoms of ocular rosacea 
when treated with tetracycline or its derivatives. The largest 
restrospective study report described improvement in 98% 
of 113 patients given either tetracycline 250 mg 4 times 
daily or doxycycline 100 mg once daily.40 Other prospective 
studies have demonstrated that between 87.5% and 100% of 
the patients have improvement of their symptoms of ocular 
rosacea after treatment with an initial dose of doxycycline 
100 mg daily.41–43 Still, randomized, placebo-controlled 
studies evaluating the efficacy of doxycycline in ocular 
rosacea are lacking.
Doxycycline versus macrolides  
in the treatment of rosacea
The first randomized, open clinical trial evaluating the 
efficacy macrolides versus doxycycline in the treatment of 
rosacea was reported in 1997.44 Patients were randomized to 
receive clarithromycin 250 mg twice daily for 4 weeks, then 
250 mg once daily for four weeks (n = 23) or doxycycline 
100 mg twice daily for 4 weeks, then 100 mg once daily for 
4 weeks (n = 17). After 8 weeks of treatment, there were no 
significant differences observed in erythema, telangiectases, 
or in the number of lesions between the two groups. Still, 
a faster decrease in lesion count was observed in the clarithro-
mycin group, showing a statistically significant (P  0.0005) 
difference in papules and pustules score between the two 
groups at weeks 4 and 6. The authors concluded that 6 weeks 
of clarithomycin treatment are as effective in the treatment 
of rosacea as 8 weeks of doxycycline treatment.
Another randomized, open clinical trial was performed 
to observe if azithromycin had an equivalent or superior 
effect to that produced by doxycycline in the treatment of 
adult patients with papulopustular rosacea.45 Patients were 
randomized to receive azithromycin 500 mg 3 times weekly 
for 1 month, then 250 mg 3 times weekly for the second 
month, and 250 mg twice weekly for the third month in the 
first group (n = 37). The second group received doxycycline 
100 mg once daily for 3 months (n = 30). In both treat-
ment groups, the mean inflammatory lesion counts were 
significantly decreased at the third month (P  0.001 in 
both groups), and at the second month post-treatment (P  
0.001 in both groups), when compared to baseline. When the 
efficacies of the two treatments were compared, there were no 
significant differences in the percentage of decrease in lesions 
(P = 0.771) or in the patients’ own assessment (P = 0.965). 
Adverse effects reported included diarrhea in four patients in 
the azithromycin group and epigastric burning in two patients 
in the doxycycline group. Only 2 patients discontinued the 
study because of adverse events, both of whom were in the 
azithromycin group. This study demonstrated that both treat-
ments were equally effective in treating inflammatory rosacea 
and that intermittent azithromycin offers an alternative in the 
management of patients with rosacea.
Doxycycline versus minocycline
Minocycline is not approved by the FDA for the treatment of 
rosacea, but it is for the treatment of acne. There are currently 
no clinical trials that have evaluated the use of minocycline 
for the treatment of rosacea and due to the lack of clinical 
evidence comparisons of efficacy with doxycycline cannot 
be drawn. Minocycline has been used as a successful, long-
term therapy for patients with acne vulgaris. Clinical trials 
of treatment of acne vulgaris with minocycline in doses of 
100 mg daily have demonstrated a statistically significant 
decrease in lesion count when compared with placebo.46 
Still, no statistically significant differences have been dem-
onstrated in clinical trials when comparing minocycline with 
doxycycline, and investigators have concluded that both are 
equally effective in the treatment of moderate to moderately 
severe acne vulgaris.47–49
An extended-release (ER) version of minocycline tablets 
at a dosage of 1 mg/kg/day (Solodyn®; Medicis Pharmaceuti-
cal Corporation) was approved in 2006 for the treatment of 
moderate-to-severe acne in patients older than 12.50 Unlike 
the anti-inflammatory dose of doxycycline 40 mg for rosacea, 
the ER version of minocycline posses antibiotic activity.
Concerns about resistance
Conventional use of tetracycline agents in the treatment of 
rosacea includes doxycycline hyclate or monohydrate (100 to 
200 mg daily), minocycline hydrochloride (100 to 200 mg 
daily), or tetracycline hydrochloride (500 to 1000 mg daily). Clinical, Cosmetic and Investigational Dermatology 2009:2 134
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These dosing regimens have proven both anti-inflammatory 
and antibiotic activity.4 Still, concerns related to increased 
bacterial resistance have been raised in the last few years 
and several common pathogens encountered in dermatology 
have demonstrated bacterial resistance, including resistance 
to tetracyclines.51
SDD 20 mg (Periostat®; CollaGenex Pharmaceuticals) 
is indicated for the treatment of adult periodontal disease, 
its mechanism having been attributed to its anticollagenase 
and antimatrix metalloproteinase properties.52,53 Studies have 
demonstrated that SDD administered twice daily for up to 
18 months does not alter or promote antibiotic susceptibility 
patterns of normal flora or opportunistic periodontal pathogens.53 
Similarly, in acne patients treated over a 6-month period 
with SDD 20 mg twice daily there was no effect on 
Propionibacterium acnes or other cutaneous commensal 
bacteria.35 Also, SDD did not alter microflora composition, 
and did not induce the emergence of organisms resistant to 
doxycycline, minocycline, tetracycline, erythromycin, clinda-
mycin, or vancomycin.35,54 Analysis of the plasma concentra-
tions of  doxycycline demonstrated that administration of 
20 mg twice daily produced maximal levels significantly lower 
than the minimum inhibitory concentration (MIC) required to 
produce an antimicrobial effect, while administration of doxy-
cycline 50 mg once daily has been proven to produce plasma 
concentrations that exceed the MIC for 2 to 3 hours.54
The lack of antibiotic resistance after treatment with 
anti-inflammatory dose doxycyline has also been previously 
demonstrated in the treatment of periodontitis.55 In a subset of 
subjects (n = 34) treated for 9 months with anti-inflammatory 
dose doxycycline 40 mg once daily, microbiologic testing 
obtained from multiple subgingival sites demonstrated no 
evidence of antimicrobial selection pressure. Also, it did 
not alter the antibiotic susceptibility of subgingival flora and 
cross-resistance was not observed.
Adverse effects
The tetracycline antibiotic class has been used safely for 
long-term therapy in patients with rosacea and acne vulgaris. 
Within this antibiotic class, doxycycline is generally well 
tolerated. Minor side effects of tetracyclines are varied; 
serious side effects are rare.56 (Table 3)
Serious drug reaction patterns to tetracycline antibiotics 
can be categorized as early or late. Early reactions include 
hypersensitivity syndrome reactions, serum-sickness-like 
reactions, and isolated single-organ dysfunction (involve-
ment of one major organ: pancreatitis, hepatitis, cutaneous 
eruptions) which occur on average within 2 months of 
treatment.57,58 Late reactions include drug-induced lupus, 
which usually occurs an average of 2 years after initiation 
of treatment.58 Drug-induced lupus has been reported in 
association with minocycline and not doxycycline use.
Second-generation tetracyclines (doxycycline hyclate, 
doxycycline monohydrate, minocycline) offer the patient the 
advantage of less frequent dosing and potentially fewer side 
effects.8,56 Based on the number of prescriptions dispensed from 
January 1, 1998 to August 31, 2003, Smith et al59 estimated 
Table 3 Adverse events with doxycycline (100 to 200 mg daily)a
Digestive system
  esophageal erosion/ulcer
  Heartburn/gastritis
  Nausea/vomits
Skin (with/without multisystemic involvement)
  Photosensitivity
  Photo-onycholysis
  Pruritus
  Allergic skin symptoms
  Acne
  Fixed drug eruption
  Acute generalized exanthematous eruption
  Hypersensitivity reaction
  Stevens-Johnson syndrome
  Sweet’s syndrome
  rash
Central nervous system
  Intracranial hypertension
  Dizziness
Urogenital system
  Vaginitis
  Vaginal candidiasis
  Vaginal dryness
  Inflamed vulva/thick white discharge
Respiratory system
  rhinitis
Other
  Hypoglycemia
  Anosmia
  Taste perversion
  Thrombocytopenia
  Minor laboratory abnormalities
  Headache
  Somnolence
  Tooth discoloration
  Temporary bone growth inhibition
aBased on case reports and clinical trials of Smith et al.59Clinical, Cosmetic and Investigational Dermatology 2009:2 135
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the overall incidence of adverse effects for doxycycline to be 
13 per million in the United States (2.3 per million per year). 
A review of the literature (case reports and clinical trials) 
revealed that esophageal erosions and photosensitivity are the 
most commonly reported adverse effects of doxycycline.59
Gastrointestinal adverse effects
The modifications in structure of the second-generation 
tetracyclines in comparison with the first-generation 
tetracyclines improve their gastrointestinal absorption. This 
increased absorption permits lower oral doses and reduces 
gastrointestinal side effects.56
Doxycycline is the most common tetracycline associated with 
gastrointestinal upset.56 The reported rates of gastrointestinal 
adverse events in clinical trials for the treatment of non-rosacea 
conditions have been found to range from 0.54% to 51.7% for 
doxycycline 100 to 200 mg daily.59
Common gastrointestinal adverse effects include 
heartburn, nausea, vomiting, diarrhea, gastritis, and 
candidiasis.56,59,60 Esophagitis and esophageal ulcerations are 
among the most severe gastrointestinal adverse events. They 
usually occur when the medication is taken before bedtime 
and with little or no water.56,60–62 Tetracyclines, particularly 
doxycycline, are the drugs implicated in most of the reported 
drug-induced esophageal ulcerations (70%).60
Doxycycline hyclate has been noted to be a common cause 
of drug-induced esophageal ulceration.56,57 The incidence of 
esophageal ulcers is greater for doxycycline hyclate capsules 
than with tablets. The capsule may stick to the mucosa of the 
esophagus if taken with little water. The ulceration results 
from the physical contact of the capsule with the epithelial 
lining of the esophagus. The identification of symptoms 
such as odynophagia, retrosternal pain and dysphagia can be 
useful in the diagnosis of a doxycycline-induced esophageal 
ulceration.60,63 The acidity of doxycycline hyclate (pH 2 to 3) 
contributes to its higher risk of esophageal ulceration when 
compared with doxycycline monohydrate (pH 5 to 6).56,57,63 
For doxycycline hyclate tablets, enteric coated delayed-release 
tablets (Doryx®; Warner Chilcott (US) Inc.) were found to 
be superior to the powder-containing tablets (Vibramycin®; 
Pfizer) when considering gastrointestinal side effects.56,64
Cutaneous adverse effects
The second most common reported adverse effect with 
doxycycline is skin reactions, which include photosensitivity, 
pruritus, and unspecified rashes.56,60,62,65 Photosensitivity and 
photo-onycholysis are reported in up to 7.5% of cases.56,57,66 
Doses of doxycycline less than 100 mg daily are a rare 
cause of photosensitivity.56,67 The relationship between the 
development of phototoxicity and doxycycline has been 
shown to be dose dependent occurring in 3% of the patients 
taking 100 mg daily, 20% of the patients at 150 mg daily and 
42% at 200 mg daily.67 Urticarial reactions may occur occa-
sionally in doxycycline-treated patients.57 The characteristic 
skin pigmentation that occurs during prolonged minocycline 
administration is not normally seen with doxycycline.56
Other less common adverse effects
Rare side effects of doxycycline include hemolytic anemia, 
thrombocytopenia, eosinophilia, and neutropenia.56,57,68 
Tetracyclines have the potential to cause benign intracranial 
hypertension (headache, photophobia, diplopia, papilledema, 
and dizziness, nausea/vomiting), which usually resolve after 
the discontinuation of the drug.56,69 A yellow-gray-brown 
tooth discoloration may occur in children.56,60,62 Recently a 
doxycycline-induced staining of teeth in an adult patient treated 
for acne was reported by Nelson et al.70 Tetracyclines may 
temporally inhibit bone growth.62 They are contraindicated in 
pregnancy (pregnancy category D), breast feeding women and 
in children younger than eight years.62 Symptoms of dizziness, 
vertigo or lightheadedness are rarely seen with doxycycline.56
Severe adverse effects associated with tetracyclines 
are rare events, nevertheless cases of doxycycline-induced 
Steven-Johnson syndrome and severe hypersensitivity 
reaction had been reported.71–74 Other uncommon reported 
doxycycline-induced skin eruptions include fixed drug 
eruption, acute generalized exanthematous pustular eruption, 
and Sweet’s syndrome.75–77
Safety of submicrobial dosage 
of doxycycline monohydrate for rosacea
No major safety concerns have been found for the SDD.31,56 The 
pooled data of reported adverse events include: nasopharyngitis, 
diarrhea, headache, upper respiratory infections, hypertension, 
sinusitis, AST elevation, abdominal pain, fungal infection, 
and influenza.31,56,78 Gastrointestinal side effects were present 
but tolerable. Marked blood pressure elevation was reported 
but not thought to be related to the study drug.31,56 No cases 
of photosensitivity have been reported to date.24,31,56 The SDD 
has shown a high safety profile.24,78
Safety of doxycycline in comparison 
with minocycline and tetracycline
Doxycycline and minocycline differ in their adverse event 
profile.59 Considerably fewer adverse effects have been 
reported for doxycycline than for minocycline; the adverse Clinical, Cosmetic and Investigational Dermatology 2009:2 136
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effects for minocycline are 5 times more common than for 
doxycycline.59
The case report data reviewed by Smith et al59 revealed 
that the predominant adverse effect secondary to doxycycline 
use is esophageal erosions. For minocycline a predominance 
of hyperpigmentation, hypersensitivity, and autoimmune-
related adverse effects was observed. Case reports do not 
necessarily represent the most common adverse events in 
the daily practice.
Based on the clinical trial data, Smith et al59 found that 
doxycycline-treated patients most commonly present with 
gastrointestinal adverse effects (gastritis, bloating, and 
cramps), while for minocycline-treated patients the central 
nervous system (dizziness) and gastrointestinal adverse 
effects were the most common.
In the treatment of acne, gastrointestinal adverse effects 
have been the most commonly reported, occurring in up 
to 20% of the doxycyline-treated patients and 25% of 
minocycline-treated patients.59 Harrison et al79 noted that 
the tolerance for doxycycline (50 mg daily) was similar to 
minocycline (50 mg daily); an excellent tolerance was found 
in 53% and 37% of the patients, respectively.
In a review conducted by Shapiro et al58 more reports of 
serious adverse events from minocycline use were observed 
in comparison with other tetracycline antibiotics. This may 
be related to the minocycline-derived reactive metabolites 
which are able to bind to tissue macromolecules causing 
direct cell damage. Minocycline metabolites may also act 
as haptens and may elicit immune responses such as drug-
induced lupus.58 To date, there are no reports of tetracycline- 
or doxycycline-induced lupus. Single-organ dysfunction 
attributable to doxycycline presents most commonly as a 
cutaneous adverse reactions (70%), whereas single-organ 
dysfunction related to minocycline most commonly presents 
as pneumonitis (45%).58
Group substitutions on the 4-ring structure of the tetra-
cycline antibiotics account for the difference in their adverse 
events profile.56,58 Doxycycline has a hydroxyl side chain 
distinguishing it from tetracycline.56,58 Minocycline shares 
the basic 4-ring structure of the other tetracyclines but has a 
substitution of a dimethylamino group in the 7th position58,80 
(Figure 1). Neither tetracycline nor doxycycline contains 
this amino acid side chain which has the potential to form 
an iminoquinone reactive metabolite.58
Extrapolating from the literature on aromatic anticonvul-
sant hypersensitivity reactions, Shapiro et al58 suggested avoid-
ing all tetracyclines in those patients who experience a serious 
adverse effect while receiving doxycyxline, minocycline, 
or tetracycline until more information on potential cross-
reactivity is available.
Relevant drug interactions
warfarin
The administration of tetracyclines to patients on chronic oral 
anticoagulation therapy may be associated with a marked 
enhancement in the anticoagulant effect.56,8184 An update of 
the clinicallysignificant drug interactions revealed doxycy-
cline as a “red flag” drug. Doxycycline is one of the 16 red 
flag drugs that account for the 80% of the clinically significant 
drug interactions. The interaction of doxycyline with warfarin 
was classified as severe and well documented.85
Penning-Van Beest et al84 found doxycycline to be the 
main antibiotic drug (in addition to amoxicillin) in daily 
practice associated with a statistically significant increase in 
the risk of bleeding when used concomitantly with warfarin; 
the relative risk, adjusted for gender and age, was 3 to 5 for 
doxycycline. The proportion of major bleedings attributable 
to the interaction of warfarin with doxycycline was estimated 
to be 18%, gastrointestinal bleeding being the most frequent 
(79%).84 The enhanced anticoagulation of warfarin by doxy-
cycline administration requires a close monitoring of the 
patient’s anticoagulation parameters.62
Pharmacodynamic as well as pharmacokinetic mechanisms 
are involved in the increased anticoagulant effect of warfarin 
when combined with doxycycline. Pharmacodynamic altera-
tion may result from the elimination of the gut flora leading to 
a secondary vitamin K deficiency (main mechanism), or may 
result from the direct inhibition of the synthesis of the vitamin 
K-dependent coagulation factors.84,85 Pharmacokinetic inter-
actions include the inhibition of the metabolism of warfarin, 
or the displacement of warfarin from plasma proteins.84 Both 
doxycycline and warfarin are mostly protein bound, 80% to 
90% and 97% respectively. Doxycycline probably displaces 
the albumin-bound warfarin with a subsequent increase in its 
fraction.83 Interaction of doxycycline with the cytochrome 
P-450 system may also alter the enzyme activity, inhibiting 
the hepatic metabolism of warfarin and thereby leading to an 
elevated plasma level and an increased risk of bleeding.83
Oral contraceptives
A possible association between the use of tetracyclines and 
failure of oral contraceptives (OCPs) had been suggested. Still, 
the true incidence of those failures is unknown.86 In an analysis 
of unplanned pregnancies reported to the Committee on 
Safety of Medicines in women taking OCPs and concominant 
antibiotics, teracyclines, and penicillins were involved in 70% Clinical, Cosmetic and Investigational Dermatology 2009:2 137
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of the reports.87 The largest numbers of apparent reported 
failures occur in women using low-dose monophasic oral 
contraceptives containing 30 µg of ethinyl estradiol.78,87
Most of the studies have not demonstrated any systematic 
interaction between antibiotics and OCPs. Evidence indicat-
ing that antibiotics alter blood concentrations of OCPs is 
lacking. Because the disposition of OCPs components is 
so variable among individuals, some women may be more 
susceptible to OCP failure.86 Modern OCP preparations 
contain smaller amounts of estrogen and have fewer drug 
interactions, which may contribute to a decrease in their 
efficacy when combined with doxycycline.86,88
In a controlled clinical trial, Neely et al89 evaluated the 
effects of doxycycline on OCPs hormone concentrations. 
No statistically significant differences in serum levels of 
ethinyl estradiol, norethindrone, or endogenous progesterone 
were seen between the control and treatment phases. How-
ever, a large inter-patient and intra-patient variability in 
ethinyl estradiol and norethindrone levels was observed. 
Neely et al89 suggested that pregnancies attributed to failure 
of OCPs because of tetracycline use could represent a true 
interaction that only manifests itself in a small proportion 
of women at risk.
Murphy et al90 found no significant decrease in the plasma 
ethinyl estradiol or norethindrone concentration in either 
short-term (24 hours) or long-term (5 to 10 days) ingestion 
of tetracycline (tetracycline 500 mg orally every 6 hours) in 
women ingesting oral contraceptives (ethinyl estradiol 35 µg 
and norethindrone 1 mg).
Archer et al91 reviewed the pharmacokinetic and the clini-
cal literature on the efficacy of oral contraceptives when used 
concomitantly with antibiotic therapy. Relevant clinical reports 
of contraceptive failure with antibiotic use were found to be 
retrospective, to have multiple potential biases, and were not 
supported by pharmacokinetic data. Archer et al91 concluded 
that the available scientific and pharmacokinetic data do not 
support the hypothesis that antibiotics, with the exception of 
rifampin, lower the efficacy of oral contraceptives.
Other drug interactions
Concomitant use of tetracycline (primarily minocycline) and 
oral retinoids has been associated with benign intracranial 
hypertension.78 It is a well-documented clinically significant 
drug interaction, where a synergistic effect of the medications 
increases the risk of pseudotumor cerebri.85
Tetracyclines can interfere with methotrexate and other 
protein bound medications by displacing them from their 
binding sites.56
Anticonvulsants (barbiturates, carbamazepine, and 
phenitoin) induce the hepatic microsomal metabolism of 
tetracyclines and consequently decrease tetracycline serum 
concentrations.62 Cholesteramine and colestipol may bind 
tetracycline and reduce gastrointestinal absorption.62
Dosing
Several oral formulations of doxycycline are currently 
approved by the FDA (Table 3), although only doxycycline 
40 mg USP (Oracea®) is approved for the treatment of rosacea. 
Doses ranging between 40 mg to 100 mg daily from 8 to 16 
weeks are most commonly used in the treatment of rosacea. 
They can be used safely in patients with renal failure.9,16
Milk, antiacids, iron supplements, and probably other 
substances with calcium, magnesium, aluminum, and iron 
have been shown to decrease tetracycline gastrointestinal 
absorption and should be ingested at least several hours 
before or after the administration of tetracyclines.62 Although 
doxycycline absorption may be less affected by these 
divalent or trivalent cations, avoiding administration within 
1 to 2 hours after ingestion of interfering food or medication 
is prudent.62 Also, the risk of esophageal ulceration reported 
Table 4 Available formulations of doxycycline92
Active ingredient Dosage form Strength Proprietary name Generic availability
Doxycycline Capsule; delayed release 40 mg Oracea No
Doxycycline monohydrate Capsule 50 mg, 75 mg, 100 mg Monodox Yes
Doxycycline hyclate Capsule 50 mg, 100 mg Vibramycin Yes
Doxycycline monohydrate Suspension 25 mg/5 mL Vibramycin Yes
Doxycycline calcium Suspension 50 mg/5 mL Vibramycin No
Doxycycline hyclate Capsule; delayed release 75 mg, 100 mg N/A Yes
Doxycycline hyclate Tablet 20 mg Periostat Yes
Doxycycline hyclate Tablet 100 mg Vibra-tabs Yes
Doxycycline hyclate Tablet; delayed release 75 mg, 100 mg, 150 mg Doryx NoClinical, Cosmetic and Investigational Dermatology 2009:2 138
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with the use of doxycycline can be minimized with adequate 
fluid intake and avoiding lying down after oral intake of 
the capsule or tablet.63 For this reason, doxycycline is best 
administered in the morning with plenty of water. Doses 
of doxycycline 100 mg daily are seldom associated with 
photosensitivity and have not been reported to date with the 
use of SDD.24,56,57 Still, patients should be warned about this 
potential side effect and advised to practice sun protection 
measures.
Conclusions
Available research and clinical experience have demonstrated 
that doxycycline safely improves the signs and symptoms 
of rosacea. Doxycycline exhibits antiangiogenic and 
anti-inflammatory properties that are effective in the treatment 
of rosacea and penetrates into normal and inflammatory tissues 
more readily than tetracycline. Also, it exhibits superior 
pharmacokinetic properties and lesser toxicity when compared 
with first-generation tetracyclines. Subantimicrobial dose 
doxycycline has not been associated with the development 
of antibiotic resistance. Anti-inflammatory dose doxycycline 
40 mg is dosed once daily improving patient compliance 
without altering antibiotic susceptibility, and having lesser 
toxicity when compared to the standard 100 mg daily dose. 
In sum, a series of clinical studies have confirmed that 
doxycycline is safe and effective as a therapeutic option in 
rosacea.
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